Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

Core Insights - Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel molecular glue degrader (MGD)-based medicines [3] - The company will host a live conference call and webcast on January 7, 2026, to present interim clinical results from the Phase 1 study of the NEK7-directed MGD MRT-8102 [1] - The presentation will include interim data from the ongoing Part 3 CRP proof-of-concept cohort targeting subjects with elevated cardiovascular disease risk [1] Company Overview - Monte Rosa Therapeutics specializes in highly selective molecular glue degrader (MGD) medicines aimed at treating serious diseases [3] - The company's QuEEN™ discovery engine utilizes AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to design MGDs with high selectivity [3] - Monte Rosa has developed a leading pipeline of first-in-class and only-in-class MGDs, with three programs currently in clinical trials [3] - The company collaborates with major pharmaceutical firms in immunology, oncology, and neurology [3]